Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bayer
Biotech
BMS oncology head swings to Syndax—Chutes & Ladders
BMS oncology head swings to Syndax. Stylus unsheathes with Bayer vet at helm. T1D Fund picks up former BMS dealmaker.
Darren Incorvaia
,
Zoey Becker
May 16, 2025 8:30am
Bayer boosts precision oncology efforts with multiyear AI deal
Apr 23, 2025 12:55pm
Bayer moves allogeneic cell therapy into ph. 3 Parkinson's trial
Jan 13, 2025 2:30am
Bayer’s hot flash drug hits goal in phase 3 breast cancer trial
Jan 9, 2025 7:40am
Sanofi scoops up China rights to Cytokinetics' heart disease med
Dec 20, 2024 11:07am
Bayer drops Huntington's gene therapy
Nov 12, 2024 10:09am
